思瑞康和维思通治疗精神分裂症的临床研究

目的　以维思通为对照组 ,探讨思瑞康治疗精神分裂症的疗效和副作用。方法　将 65例符合CCMD 3的精神分裂症患者随机分为两组 ,分别给予思瑞康和维思通治疗 8周。采用阳性症状和阴性症状量表 (PANSS)评定临床疗效 ,副反应量表 (TESS)评定副反应。结果　治疗 8周后的疗效相当 (P >0 .0 5 ) ;思瑞康组和维思通组的显效率差异无显著性 (P >0 . 0 5 ) ;思瑞康组的副反应发生率低于维思通组 ,但差异无显著性 (P >0 . 0 5 ) ;维思通组锥体外系副反应和内分泌改变的发生率均明显高于思瑞康组 (P <0. 0 5 ) ,但两药引起的副反应一般为轻度或中度 ,患者耐受性较好。结论　思瑞康和维思通对精神分裂症的疗效相当 ,但副作用有所不同。

COMPARISON OF EFFICACY AND SAFETY OF SEROQUEL AND RESPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA

Objective To investigate the clinical efficacy and side effects of quesetiapine in the treatment of schizophrenia. Methods 65 patients with schizophrenia by CCMD-3 were randomly allocated to 2 groups treated with seroquel or risperidone for 8 weeks. The Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Symptoms Scale (TESS) were used to evaluate efficacy and adverse effects respectively before and at the end of 2, 4, 8 weeks of treatment. Results The therapeutic efficacy in group was similar to that in risperidone (P>0.05); There was no significant difference between the two groups (P>0.05). Incidence of adverse effects in the quetiapine group was lower than that in the risperidone group, but the difference was not significant (P>0.05). The rates of extra-pyramidal symptoms and endocrine change were significantly higher in the risperidone group than those in the quetiapine group (P<0.05). But these side effects were not serious, and patients often had good torlerability for them. Conclusions The results suggest that seroquel is as effective as risperidone for the treatment of schizophrenia, but the 2 agents have different side effects.